Abstract: Apparatuses for controlling fluid flow are important components for delivering process fluids for semiconductor fabrication. These apparatuses for controlling fluid flow require a variety of fluid flow components which are tightly packaged within the apparatuses for controlling flow. In an effort to improve packaging density, fluid delivery modules preferably incorporate both active and passive components into a single substrate block. This enables increases in packaging density as well as enabling reduced cost through greater simplification of the fluid delivery module. For instance, incorporating a filter to filter incoming fluid with a valve or other component in a single monolithic block avoids the need for separate components which add cost and complexity.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: A method for manufacturing a three dimensional object includes steps of: providing a digital description of the object as a set of voxels; sequentially creating an actual set of voxels corresponding to the digital set of voxels. At least one voxel comprises a polymer derived from: polyol and an ionic monomer. The calculated charge density of the resulting polymer is 0.01 to 0.7 mEq/g. A three-dimensional object having at least one voxel. The at least one voxel including a polymer derived from: a polyol and an ionic monomer, and the calculated charge density of the resulting polymer is 0.01 to 0.7 mEq/g.

Abstract: Apparatuses for controlling gas flow are important components for delivering process gases for semiconductor fabrication. These apparatuses for controlling gas flow frequently rely on flow restrictors which can provide a known flow impedance of the process gas. In one embodiment, a flow restrictor is disclosed, the flow restrictor constructed of a plurality of layers, one or more of the layers having a flow passage therein that extends from a first aperture at a first end of the flow restrictor to a second aperture at a second end of the flow restrictor.

Abstract: Aspects of the subject disclosure may include, for example, receiving, by a processing system including a processor that is operative in a first communication network, a certificate from a communication device that is operative in a second communication network, extracting, by the processing system, an identifier of the communication device from the certificate, authenticating, by the processing system, the communication device in accordance with the identifier, comparing, by the processing system, the identifier with a plurality of identifiers to determine that the communication device is authorized to access data, resulting in an authorization determination, and transmitting, by the processing system, the data to the communication device based on the authorization determination. Other embodiments are disclosed.

Abstract: A secure storage system for limiting access to a stored material, the storage system including a remote access management system including an input device for receiving an access instruction and a transmitting device configured to electronically transmit an access instruction signal based on the access instruction, a cabinet including at least one storage drawer including a first lock, at least one container arranged in the at least one storage drawer each at least one container configured to store a stored material, each at least one container including a second lock for preventing access to the stored material. The second lock is placed in an unlocked state allowing access to the stored material based on the access instruction signal received from the remote access management system. A switch indicates to the remote access management system a locked state or an unlocked state of the respective container.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: A first feature is displayed within a first view of a user interface. A first selection of the first feature is configured to display a first set of identifiers corresponding to one or more tasks. A second feature is displayed within the first view of the user interface. A second selection of the second feature is configured to display a second set of identifiers corresponding to a set of workers. Each worker of the set of workers is associated with the one or more tasks and a first time that the one or more tasks are scheduled to be completed by. A set of status indicators are displayed. Each status indicator of the set of status indicators indicates whether the one or more tasks have been completed by the first time for the each worker of the set of workers based at least in part on the associating.

Abstract: A gas flow control system for delivering a plurality of gas flows. The gas flow control system has a gas flow path extending from a gas inlet to first and second gas outlets. First and second flow restrictors are operably coupled to the gas flow path. First and second valves are operably coupled to the gas flow path such that when both first and second valves are in a fully open state, flows of gas from the first and second gas outlets are split according to the impedances of the first and second flow restrictors.

Abstract: The present invention relates to relates to a polymer formulation for three-dimensionally (3D) printing an article by stereolithography, the formulation comprising a functionalized polymer. The invention further relates to lithographic methods to form 3D objects that incorporate the aforementioned polymer formulation.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: A first feature is displayed within a first view of a user interface. A first selection of the first feature is configured to display a first set of identifiers corresponding to one or more tasks. A second feature is displayed within the first view of the user interface. A second selection of the second feature is configured to display a second set of identifiers corresponding to a set of workers. Each worker of the set of workers is associated with the one or more tasks and a first time that the one or more tasks are scheduled to be completed by. A set of status indicators are displayed. Each status indicator of the set of status indicators indicates whether the one or more tasks have been completed by the first time for the each worker of the set of workers based at least in part on the associating.

Abstract: A secure storage system for limiting access to a stored material, the storage system including a remote access management system including an input device for receiving an access instruction and a transmitting device configured to electronically transmit an access instruction signal based on the access instruction, a cabinet including at least one storage drawer including a first lock, at least one container arranged in the at least one storage drawer each at least one container configured to store a stored material, each at least one container including a second lock for preventing access to the stored material. The second lock is placed in an unlocked state allowing access to the stored material based on the access instruction signal received from the remote access management system. A switch indicates to the remote access management system a locked state or an unlocked state of the respective container.

Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Abstract: The present disclosure relates to deuterated forms of oxytocin, carbetocin and analogs thereof. The disclosed deuterated compounds may have similar biochemical potency and selectivity as the parent compound, and, in select instances, the selective deuteration may enable substantial benefits to their overall therapeutic profile, such as reduced adverse side effects with a decreased metabolic liability, extended pharmacological effective life, enhanced subject compliance, and/or may also decrease population pharmacokinetic variability. The present disclosure also includes pharmaceutical compositions of deuterated compounds, which may be used to treat various diseases and conditions.